- SEK1.45bn
- SEK1.36bn
- SEK313.35m
Brief: Paxman Receives First Order From Teva In Mexico
Brief: Paxman comments on AMA decision on CPT code for scalp cooling
Brief: Paxman Q1 Operating Loss Narrows To SEK 1.6 Million
Brief: Paxman Supplements Application For Expanded FDA Clearance In USA
Brief: Paxman Receives Market Approval In Mexico
Brief: Paxman Submits Application For Market Approval In Japan
Brief: PAXMAN Reaches Milestone Of 250 Scalp Cooling Systems In The USA
Brief: Paxman Q4 Net Sales At SEK 9.0 Million
Brief: Paxman Enters Into Alliance With IR-Bureau Honeybadger
Brief: Paxman Signs Agreement With Anderson Cancer Center
Brief: PAXMAN And Teva Announce Licensing Agreement
Brief: Paxman Receives SEK 10 Mln Line Of Credit As Financial Buffer
Brief: Paxman Q3 operating loss at SEK 2.5 mln
Brief: Paxman applies for FDA approval for increased use of scalp cooling system
Brief: Paxman Q2 2017 net sales at SEK 7.1 million
Brief: Paxman's scalp cooling system approved by ANMAT in Argentina
Brief: Paxman gets approval from Taiwan Food and Drug Administration for scalp cooling system